Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.

Nordmark A, Andersson A, Baranczewski P, Wanag E, Ståhle L.

Eur J Clin Pharmacol. 2014 Feb;70(2):167-78. doi: 10.1007/s00228-013-1603-8. Epub 2013 Nov 2.

PMID:
24186263
2.

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X.

Br J Clin Pharmacol. 2009 Dec;68(6):928-35. doi: 10.1111/j.1365-2125.2009.03548.x.

3.

Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.

Walzer M, Bekersky I, Blum RA, Tolbert D.

Pharmacotherapy. 2012 Apr;32(4):340-53. doi: 10.1002/j.1875-9114.2012.01028.x. Epub 2012 Mar 15.

PMID:
22422635
4.
5.

Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Barter ZE, Tucker GT, Rowland-Yeo K.

Clin Pharmacokinet. 2013 Dec;52(12):1085-100. doi: 10.1007/s40262-013-0089-y.

PMID:
23818090
6.

A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation.

Peng Y, Wu H, Zhang X, Zhang F, Qi H, Zhong Y, Wang Y, Sang H, Wang G, Sun J.

Xenobiotica. 2015;45(11):961-77. doi: 10.3109/00498254.2015.1036954. Epub 2015 May 26.

PMID:
26007223
7.

Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.

Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A.

Eur J Clin Pharmacol. 2006 Apr;62(4):277-84. Epub 2006 Mar 7.

PMID:
16525816
8.

In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.

Derks M, Fowler S, Kuhlmann O.

Curr Med Res Opin. 2009 Apr;25(4):891-902. doi: 10.1185/03007990902790928 .

PMID:
19245299
9.

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD.

J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.

PMID:
16639344
10.

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.

Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatté T, Fuhr U.

Eur J Clin Pharmacol. 2012 May;68(5):553-60. doi: 10.1007/s00228-011-1174-5. Epub 2011 Dec 21.

11.

Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.

Zheng L, Lu Y, Cao X, Huang Y, Liu Y, Tang L, Liao SG, Wang AM, Li YJ, Lan YY, Wang YL.

J Ethnopharmacol. 2014 Dec 2;158 Pt A:276-82. doi: 10.1016/j.jep.2014.10.031. Epub 2014 Oct 29.

PMID:
25446640
12.

Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

Blakey GE, Lockton JA, Perrett J, Norwood P, Russell M, Aherne Z, Plume J.

Br J Clin Pharmacol. 2004 Feb;57(2):162-9.

13.

Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.

Derungs A, Donzelli M, Berger B, Noppen C, Krähenbühl S, Haschke M.

Clin Pharmacokinet. 2016 Jan;55(1):79-91. doi: 10.1007/s40262-015-0294-y.

14.

An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS.

Otten JN, Hingorani GP, Hartley DP, Kragerud SD, Franklin RB.

Drug Metab Lett. 2011 Jan;5(1):17-24.

PMID:
21198441
15.

Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.

Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS.

Eur J Clin Pharmacol. 2010 Jan;66(1):67-76. doi: 10.1007/s00228-009-0716-6. Epub 2009 Sep 16.

PMID:
19756558
17.

The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krähenbühl S, Haschke M.

Clin Pharmacokinet. 2014 Mar;53(3):271-82. doi: 10.1007/s40262-013-0115-0.

PMID:
24218006
18.

Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.

Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG.

Clin Pharmacol Ther. 2007 Nov;82(5):531-40. Epub 2007 Mar 28. Erratum in: Clin Pharmacol Ther. 2010 Aug;88(2):275. Dosage error in article text.

PMID:
17392720
19.

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr.

Clin Pharmacol Ther. 2000 Oct;68(4):375-83.

PMID:
11061577
20.

Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.

Micuda S, Mundlova L, Anzenbacherova E, Anzenbacher P, Chladek J, Fuksa L, Martinkova J.

Eur J Clin Pharmacol. 2004 Oct;60(8):583-9. Epub 2004 Sep 16.

PMID:
15378224
Items per page

Supplemental Content

Write to the Help Desk